DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

Simponi (Golimumab) - Published Studies

 
 



Simponi Related Published Studies

Well-designed clinical trials related to Simponi (Golimumab)

The effect of intravenous golimumab on health-related quality of life in rheumatoid arthritis: 24-week results of the phase III GO-FURTHER trial. [2014]

Safety and efficacy of golimumab in Chinese patients with active ankylosing spondylitis: 1-year results of a multicentre, randomized, double-blind, placebo-controlled phase III trial. [2014]

Golimumab reduces disease activity of rheumatoid arthritis for 1 year and strongly inhibits radiographic progression in Japanese patients: partial but detailed results of the GO-FORTH and GO-MONO studies. [2013]

Comparison of three enthesitis indices in a multicentre, randomized, placebo-controlled trial of golimumab in ankylosing spondylitis (GO-RAISE). [2013]

Tocilizumab inhibits progression of joint damage in rheumatoid arthritis irrespective of its anti-inflammatory effects: disassociation of the link between inflammation and destruction. [2012]

Golimumab administered subcutaneously every 4 weeks in ankylosing spondylitis: 104-week results of the GO-RAISE study. [2012]

The effects of golimumab on radiographic progression in rheumatoid arthritis: results of randomized controlled studies of golimumab before methotrexate therapy and golimumab after methotrexate therapy. [2011.05]

Population approach for exposure-response modeling of golimumab in patients with rheumatoid arthritis. [2011.05]

Population pharmacokinetics of golimumab in patients with ankylosing spondylitis: impact of body weight and immunogenicity. [2010.09]

Golimumab reduces sleep disturbance in patients with active ankylosing spondylitis: results from a randomized, placebo-controlled trial. [2010.09]

Lack of racial differences in the pharmacokinetics of subcutaneous golimumab in healthy Japanese and Caucasian male subjects. [2010.07]

Golimumab in patients with active rheumatoid arthritis despite methotrexate therapy: 52-week results of the GO-FORWARD study. [2010.06]

Golimumab, a new human anti-tumor necrosis factor alpha antibody, administered intravenously in patients with active rheumatoid arthritis: Forty-eight-week efficacy and safety results of a phase III randomized, double-blind, placebo-controlled study. [2010.04]

Subcutaneous bioavailability of golimumab at 3 different injection sites in healthy subjects. [2010.03]

Association of serum markers with improvement in clinical response measures after treatment with golimumab in patients with active rheumatoid arthritis despite receiving methotrexate: results from the GO-FORWARD study. [2010]

Golimumab, a new human anti-tumor necrosis factor alpha antibody, administered intravenously in patients with active rheumatoid arthritis: Forty-eight-week efficacy and safety results of a phase III randomized, double-blind, placebo-controlled study. [2010]

Population pharmacokinetics of golimumab, an anti-tumor necrosis factor-alpha human monoclonal antibody, in patients with psoriatic arthritis. [2009.09]

Golimumab, a human anti-tumor necrosis factor alpha monoclonal antibody, injected subcutaneously every four weeks in methotrexate-naive patients with active rheumatoid arthritis: twenty-four-week results of a phase III, multicenter, randomized, double-blind, placebo-controlled study of golimumab before methotrexate as first-line therapy for early-onset rheumatoid arthritis. [2009.08]

Golimumab in patients with active rheumatoid arthritis after treatment with tumour necrosis factor alpha inhibitors (GO-AFTER study): a multicentre, randomised, double-blind, placebo-controlled, phase III trial. [2009.07.18]

E-selectin, interleukin 18, serum amyloid a, and matrix metalloproteinase 9 are associated with clinical response to golimumab plus methotrexate in patients with active rheumatoid arthritis despite methotrexate therapy. [2009.07]

Golimumab, a human antibody to tumour necrosis factor {alpha} given by monthly subcutaneous injections, in active rheumatoid arthritis despite methotrexate therapy: the GO-FORWARD Study. [2009.06]

Golimumab, a new human tumor necrosis factor alpha antibody, administered every four weeks as a subcutaneous injection in psoriatic arthritis: Twenty-four-week efficacy and safety results of a randomized, placebo-controlled study. [2009.04]

Efficacy and safety of golimumab in patients with ankylosing spondylitis: results of a randomized, double-blind, placebo-controlled, phase III trial. [2008.11]

Golimumab in patients with active rheumatoid arthritis despite treatment with methotrexate: a randomized, double-blind, placebo-controlled, dose-ranging study. [2008.04]

Pharmacokinetics and safety of golimumab, a fully human anti-TNF-alpha monoclonal antibody, in subjects with rheumatoid arthritis. [2007.03]

Well-designed clinical trials possibly related to Simponi (Golimumab)

The comparative safety of tumor necrosis factor inhibitors in rheumatoid arthritis: a meta-analysis update of 44 trials. [2014]

A mixed treatment comparison of the short-term efficacy of biologic disease modifying anti-rheumatic drugs in established rheumatoid arthritis. [2011.10]

Focal fat lesions at vertebral corners on magnetic resonance imaging predict the development of new syndesmophytes in ankylosing spondylitis. [2011.08]

The number needed to treat for second-generation biologics when treating established rheumatoid arthritis: a systematic quantitative review of randomized controlled trials. [2011.01]

A randomized, double-blind, placebo-controlled study of tumor necrosis factor-alpha blockade in severe persistent asthma. [2009.04.01]

Other research related to Simponi (Golimumab)

Comparison of composite measures of disease activity in psoriatic arthritis using data from an interventional study with golimumab. [2014]

Comprehensive tuberculosis screening program in patients with inflammatory arthritides treated with golimumab, a human anti-tumor necrosis factor antibody, in Phase III clinical trials. [2013]

Treatment of psoriatic arthritis with tumor necrosis factor inhibitors: longer-term outcomes including enthesitis and dactylitis with golimumab treatment in the Longterm Extension of a Randomized, Placebo-controlled Study (GO-REVEAL). [2012]

Significant improvement in synovitis, osteitis, and bone erosion following golimumab and methotrexate combination therapy as compared with methotrexate alone: A magnetic resonance imaging study of 318 methotrexate-naive rheumatoid arthritis patients. [2011.12]

Maintenance of efficacy and safety with subcutaneous golimumab among patients with active rheumatoid arthritis who previously received intravenous golimumab. [2011.12]

Golimumab reduces spinal inflammation in ankylosing spondylitis: MRI results of the randomised, placebo- controlled GO-RAISE study. [2011.11.29]

Golimumab in combination with methotrexate in Japanese patients with active rheumatoid arthritis: results of the GO-FORTH study. [2011.11.25]

Golimumab administered subcutaneously every 4 weeks in ankylosing spondylitis: 104-week results of the GO-RAISE study. [2011.11.11]

Assessment by MRI of inflammation and damage in rheumatoid arthritis patients with methotrexate inadequate response receiving golimumab: results of the GO-FORWARD trial. [2011.11]

Serum markers associated with clinical improvement in patients with ankylosing spondylitis treated with golimumab. [2011.10.28]

Golimumab and immunogenicity? 2010 and beyond. [2011.04]

Golimumab - a new tool in the armoury against inflammatory arthritis. [2011.03]

Dermatologic adverse events: golimumab, friend or foe? [2011.01]

Golimumab for the treatment of psoriatic arthritis. [2011]

The effects of golimumab on radiographic progression in rheumatoid arthritis: results of randomized controlled studies of golimumab before methotrexate therapy and golimumab after methotrexate therapy. [2011]

Golimumab: Review of the efficacy and tolerability of a recently approved tumor necrosis factor-alpha inhibitor. [2010.09]

A latent variable approach for modeling categorical endpoints among patients with rheumatoid arthritis treated with golimumab plus methotrexate. [2010.08]

Golimumab therapy of rheumatoid arthritis: an overview. [2010.08]

Population Approach for Exposure-Response Modeling of Golimumab in Patients With Rheumatoid Arthritis. [2010.07.09]

The efficacy and safety of golimumab in the treatment of arthritis. [2010.07]

Golimumab: A novel human anti-TNF-alpha monoclonal antibody for the treatment of rheumatoid arthritis, ankylosing spondylitis, and psoriatic arthritis. [2010.06.15]

Golimumab for rheumatoid arthritis: a systematic review. [2010.06]

Golimumab for rheumatoid arthritis. [2010.01.20]

Golimumab: A novel anti-TNF-alpha human monoclonal antibody for rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis. [2010.01]

Population pharmacokinetics of golimumab in patients with ankylosing spondylitis: impact of body weight and immunogenicity. [2010]

Golimumab reduces sleep disturbance in patients with active ankylosing spondylitis: results from a randomized, placebo-controlled trial. [2010]

The efficacy and safety of golimumab in the treatment of arthritis. [2010]

Golimumab in patients with active rheumatoid arthritis despite methotrexate therapy: 52-week results of the GO-FORWARD study. [2010]

Golimumab for rheumatoid arthritis: a systematic review. [2010]

Lack of racial differences in the pharmacokinetics of subcutaneous golimumab in healthy Japanese and Caucasian male subjects. [2010]

Tocilizumab for rheumatoid arthritis. [2010]

Subcutaneous bioavailability of golimumab at 3 different injection sites in healthy subjects. [2010]

Golimumab. [2009.09]

Which measure of inflammation to use? A comparison of erythrocyte sedimentation rate and C-reactive protein measurements from randomized clinical trials of golimumab in rheumatoid arthritis. [2009.08]

Golimumab: in the treatment of rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis. [2009]

Golimumab, a fully human monoclonal antibody against TNFalpha. [2008.08]

Other possibly related research studies

Gateways to clinical trials. [2010.04]

Current evidence for the management of rheumatoid arthritis with biological disease-modifying antirheumatic drugs: a systematic literature review informing the EULAR recommendations for the management of RA. [2010.06]

Safety and efficacy of the tumor necrosis factor antagonists. [2010.03]

Description of the efficacy and safety of three new biologics in the treatment of rheumatoid arthritis. [2010.03]

Newer biological agents in rheumatoid arthritis: impact on health-related quality of life and productivity. [2010]

[Recombinant proteins or monoclonal antibodies: comparative properties and interest in rheumatoid arthritis] [2009.12]

Novel TNF antagonists for the treatment of rheumatoid arthritis. [2010.01]

[Copernican revolution in the therapy of rheumatoid arthritis: the contribution of anti-TNFalpha drugs] [2009.04]

Gateways to clinical trials. [2009.10]

TNF-alpha inhibitors in asthma and COPD: we must not throw the baby out with the bath water. [2010.04]

Tumor necrosis factor-alpha antagonists: differential clinical effects by different biotechnological molecules. [2009.07]

Gateways to clinical trials. [2009.07]

Update on the treatment of peripheral arthritis in psoriatic arthritis. [2009.08]

[Biologic therapies in chronic inflammatory bowel diseases] [2009.05]

[Biological therapies in rheumatology] [2009.05]

[New biologic and non biologic disease modifying anti-rheumatic drugs for rheumatoid arthritis] [2009.06]

Biological therapy of inflammatory bowel disease. [2009.01]

Prospective new biological therapies for rheumatoid arthritis. [2009.12]

[Biologic therapies in the treatment of psoriasis] [2009.05]

New biologics for psoriasis and psoriatic arthritis. [2009.01]

Biologic agents for rheumatoid arthritis: 2008 and beyond. [2009.01]

Emerging therapeutics for rheumatoid arthritis. [2008]

Gateways to clinical trials. [2008.05]

Biologic agents in rheumatoid arthritis: an update for managed care professionals. [2011.11]

A dose-response meta-analysis for quantifying relative efficacy of biologics in rheumatoid arthritis. [2011.12]

Non-infectious pulmonary complications of newer biological agents for rheumatic diseases--a systematic literature review. [2011.12]

A mixed treatment comparison of the efficacy of anti-TNF agents in rheumatoid arthritis for methotrexate non-responders demonstrates differences between treatments: a Bayesian approach. [2011.09.29]

Exploratory analyses of the association of MRI with clinical, laboratory and radiographic findings in patients with rheumatoid arthritis. [2011.12]

Associations between body mass, radiographic joint damage, adipokines and risk factors for bone loss in rheumatoid arthritis. [2011.11]

Indirect comparison of biological treatments in refractory rheumatoid arthritis. [2011.08.10]

Safety of anti-tumour necrosis factor agents in patients with chronic hepatitis C infection: a systematic review. [2011.09]

Cytokine modulators in the treatment of sarcoidosis. [2011.12]

Advances in rheumatology: new targeted therapeutics. [2011.05.25]

[Effectiveness of biological treatments based on ACR70 response in rheumatoid arthritis: indirect comparison and meta-regression using Bayes-model]. [2011.06.05]

Adalimumab for the treatment of immune-mediated diseases: an update on old and recent indications. [2011.04]

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017